Extracellular matrix remodeling following myocardial infarction influences the therapeutic potential of mesenchymal stem cells

Stem Cell Research and Therapy

Volumn 5, Issue 1, 2014, Pages

  Sullivan, Kelly Elizabeth ^a   Quinn, Kyle Patrick ^a   Tang, Katherine Michele ^a   Georgakoudi, Irene ^a   Black, Lauren Deems ^a,b  

^a Tufts University   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GATA4 PROTEIN, RAT; HOMEODOMAIN PROTEIN; NKX2.5 PROTEIN, RAT; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 4;

ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; EXTRACELLULAR MATRIX; GENETICS; HEART MUSCLE CELL; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MYOCARDIAL INFARCTION; PARACRINE SIGNALING; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; CHEMOKINE CXCL12; EXTRACELLULAR MATRIX; GATA4 TRANSCRIPTION FACTOR; HEPATOCYTE GROWTH FACTOR; HOMEODOMAIN PROTEINS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; PARACRINE COMMUNICATION; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTORS;

EID: 84892776788     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt403     Document Type: Article

References (81)

1. Heart disease and stroke statistics, 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y, Circulation 2007 115 69 e171 10.1161/CIRCULATIONAHA.106.179918 17194875 (Pubitemid 46226160)
2. Cell therapy attenuates cardiac dysfunction post myocardial infarction: effect of timing, routes of injection and a fibrin scaffold. Nakamuta JS, Danoviz ME, Marques FLN, dos Santos L, Becker C, Gonçalves GA, Vassallo PF, Schettert IT, Tucci PJF, Krieger JE, PLoS One 2009 4 6005 10.1371/journal.pone.0006005 19547700
3. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A, Circulation 2009 120 408 416 10.1161/CIRCULATIONAHA.109. 865154 19620500
4. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE, J Mol Cell Cardiol 2001 33 907 921 10.1006/jmcc.2001.1367 11343414 (Pubitemid 32545326)
5. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Berry MF, Engler AJ, Woo YJ, Pirolli TJ, Bish LT, Jayasankar V, Morine KJ, Gardner TJ, Discher DE, Sweeney HL, Am J Physiol Heart Circ Physiol 2006 290 2196 H2203 10.1152/ajpheart.01017.2005 16473959 (Pubitemid 43846045)
6. Cell therapy for acute myocardial infarction: where are we heading? Wollert KC, Drexler H, Nat Clin Pract Cardiovasc Med 2004 1 61 10.1038/ncpcardio0053 16265288 (Pubitemid 40823695)
7. Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction. Guo J, Lin G, Bao C, Hu Z, Hu M, Inflammation 2007 30 97 104 10.1007/s10753-007-9025-3 17497204 (Pubitemid 46985774)
8. The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches. Das R, Jahr H, van Osch GJVM, Farrell E, Tissue Eng Part B Rev 2010 16 159 168 10.1089/ten.teb.2009.0296 19698058
9. In vivo myocardial distribution of multipotent progenitor cells following intracoronary delivery in a swine model of myocardial infarction. Ly HQ, Hoshino K, Pomerantseva I, Kawase Y, Yoneyama R, Takewa Y, Fortier A, Gibbs-Strauss SL, Vooght C, Frangioni JV, Hajjar RJ, Eur Heart J 2009 30 2861 2868 10.1093/eurheartj/ehp322 19687154
10. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Cleland JGF, Freemantle N, Coletta AP, Clark AL, Eur J Heart Fail 2006 8 105 110 10.1016/j.ejheart.2005. 12.003 16387630 (Pubitemid 43012109)
11. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang J-A, Wei L, J Thorac Cardiovasc Surg 2008 135 799 808 10.1016/j.jtcvs.2007.07.071 18374759 (Pubitemid 351417929)
12. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Mirotsou M, Zhang Z, Deb A, Zhang L, Gnecchi M, Noiseux N, Mu H, Pachori A, Dzau V, Proc Natl Acad Sci U S A 2007 104 1643 1648 10.1073/pnas.0610024104 17251350 (Pubitemid 46214644)
13. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Tang YL, Zhao Q, Qin X, Shen L, Cheng L, Ge J, Phillips MI, Ann Thorac Surg 2005 80 229 236 discussion 236-237 10.1016/j.athoracsur.2005.02.072 15975372 (Pubitemid 40840214)
14. Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. Hocking AM, Gibran NS, Exp Cell Res 2010 316 2213 2219 10.1016/j.yexcr.2010.05.009 20471978
15. Importance of the SDF-1:CXCR4 axis in myocardial repair. Penn MS, Circ Res 2009 104 1133 1135 10.1161/CIRCRESAHA.109.198929 19461103
16. Paracrine mechanisms in adult stem cell signaling and therapy. Gnecchi M, Zhang Z, Ni A, Dzau VJ, Circ Res 2008 103 1204 1219 10.1161/CIRCRESAHA.108. 176826 19028920
17. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Ranganath SH, Levy O, Inamdar MS, Karp JM, Cell Stem Cell 2012 10 244 258 10.1016/j.stem.2012.02.005 22385653
18. The role of cardiac fibroblasts in extracellular matrix-mediated signaling during normal and pathological cardiac development. Sullivan KE, Black LD, J Biomech Eng 2013 135 71001 10.1115/1.4024349 23720014
19. The extracellular matrix: at the center of it all. Bowers SLK, Banerjee I, Baudino TA, J Mol Cell Cardiol 2010 48 474 482 10.1016/j.yjmcc.2009.08.024 19729019
20. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. Kim S-H, Turnbull J, Guimond S, J Endocrinol 2011 209 139 151 10.1530/JOE-10-0377 21307119
21. Regulation of development and differentiation by the extracellular matrix. Adams JC, Watt FM, Development 1993 117 1183 1198 8404525 (Pubitemid 23154486)
22. Differential effect of myocardial matrix and integrins on cardiac differentiation of human mesenchymal stem cells. Tan G, Shim W, Gu Y, Qian L, Chung YY, Lim SY, Yong P, Sim E, Wong P, Differentiation 2010 79 260 271 10.1016/j.diff.2010.02.005 20307924
23. Matrix elasticity directs stem cell lineage specification. Engler AJ, Sen S, Sweeney HL, Discher DE, Cell 2006 126 677 689 10.1016/j.cell.2006.06.044 16923388 (Pubitemid 44233625)
24. Intrinsic extracellular matrix properties regulate stem cell differentiation. Reilly GC, Engler AJ, J Biomech 2010 43 55 62 10.1016/j.jbiomech.2009.09.009 19800626
25. Directing osteogenic and myogenic differentiation of MSCs: interplay of stiffness and adhesive ligand presentation. Rowlands AS, George PA, Cooper-White JJ, Am J Physiol Cell Physiol 2008 295 1037 C1044 10.1152/ajpcell.67.2008 18753317
26. Absence of filamin A prevents cells from responding to stiffness gradients on gels coated with collagen but not fibronectin. Byfield FJ, Wen Q, Levental I, Nordstrom K, Arratia PE, Miller RT, Janmey PA, Biophys J 2009 96 5095 5102 10.1016/j.bpj.2009.03.046 19527669
27. Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Ieda M, Tsuchihashi T, Ivey KN, Ross RS, Hong T-T, Shaw RM, Srivastava D, Dev Cell 2009 16 233 244 10.1016/j.devcel.2008.12.007 19217425
28. Mesenchymal stem cells ability to generate traction stress in response to substrate stiffness is modulated by the changing extracellular matrix composition of the heart during development. Gershlak JR, Resnikoff JIN, Sullivan KE, Williams C, Wang RM, Black LD, Biochem Biophys Res Commun 2013 439 161 166 10.1016/j.bbrc.2013.08.074 23994333
29. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Ott HC, Matthiesen TS, Goh S-K, Black LD, Kren SM, Netoff TI, Taylor DA, Nat Med 2008 14 213 221 10.1038/nm1684 18193059 (Pubitemid 351214548)
30. Young developmental age cardiac extracellular matrix promotes the expansion of neonatal cardiomyocytes in vitro. Williams C, Quinn KP, Georgakoudi I, Black LD, Acta Biomater 2014 10 194 204 10.1016/j.actbio.2013.08.037 24012606
31. A naturally derived cardiac extracellular matrix enhances cardiac progenitor cell behavior in vitro. French KM, Boopathy AV, DeQuach JA, Chingozha L, Lu H, Christman KL, Davis ME, Acta Biomater 2012 8 4357 4364 10.1016/j.actbio.2012.07.033 22842035
32. Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Singelyn JM, DeQuach JA, Seif-Naraghi SB, Littlefield RB, Schup-Magoffin PJ, Christman KL, Biomaterials 2009 30 5409 5416 10.1016/j.biomaterials.2009.06.045 19608268
33. Evolution of scar structure, mechanics, and ventricular function after myocardial infarction in the rat. Fomovsky GM, Holmes JW, Am J Physiol Heart Circ Physiol 2010 298 221 H228 10.1152/ajpheart.00495.2009 19897714
34. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JE, Valdes D, Pattany PM, Zambrano JP, Hu Q, McNiece I, Heldman AW, Hare JM, Proc Natl Acad Sci U S A 2009 106 14022 14027 10.1073/pnas.0903201106 19666564
35. Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitro. Rose RA, Jiang H, Wang X, Helke S, Tsoporis JN, Gong N, Keating SCJ, Parker TG, Backx PH, Keating A, Stem Cells 2008 26 2884 2892 10.1634/stemcells.2008-0329 18687994
36. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Noiseux N, Gnecchi M, Lopez-Ilasaca M, Zhang L, Solomon SD, Deb A, Dzau VJ, Pratt RE, Mol Ther 2006 14 840 850 10.1016/j.ymthe.2006.05.016 16965940 (Pubitemid 44752717)
37. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ, Nat Med 2003 9 1195 1201 10.1038/nm912 12910262 (Pubitemid 37173705)
38. Characterization of metabolic changes associated with the functional development of 3D engineered tissues by non-invasive, dynamic measurement of individual cell redox ratios. Quinn KP, Bellas E, Fourligas N, Lee K, Kaplan DL, Georgakoudi I, Biomaterials 2012 33 5341 5348 10.1016/j.biomaterials.2012.04. 024 22560200
39. Effects of elastase on the mechanical and failure properties of engineered elastin-rich matrices. Black LD, Brewer KK, Morris SM, Schreiber BM, Toselli P, Nugent MA, Suki B, Stone PJ, J Appl Physiol 2005 98 1434 1441 10.1152/japplphysiol.00921.2004 15640390 (Pubitemid 40396521)
40. Macro design, structure, and mechanics of the left ventricle. Spotnitz HM, J Thorac Cardiovasc Surg 2000 119 1053 1077 10.1016/S0022-5223(00)70106-1 10788831
41. Simple and high yielding method for preparing tissue specific extracellular matrix coatings for cell culture. DeQuach JA, Mezzano V, Miglani A, Lange S, Keller GM, Sheikh F, Christman KL, PLoS One 2010 5 13039 10.1371/journal.pone.0013039 20885963
42. Preparation and rheological characterization of a gel form of the porcine urinary bladder matrix. Freytes DO, Martin J, Velankar SS, Lee AS, Badylak SF, Biomaterials 2008 29 1630 1637 10.1016/j.biomaterials.2007.12.014 18201760
43. Preparation of a flexible, porous polyacrylamide substrate for mechanical studies of cultured cells. Wang YL, Pelham RJ, Methods Enzymol 1998 298 489 496 9751904
44. Cyclic distension of fibrin-based tissue constructs: evidence of adaptation during growth of engineered connective tissue. Syedain ZH, Weinberg JS, Tranquillo RT, Proc Natl Acad Sci U S A 2008 105 6537 6542 10.1073/pnas.0711217105 18436647 (Pubitemid 351754542)
45. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, J Clin Invest 2000 106 1511 1519 10.1172/JCI10226 11120758 (Pubitemid 32038589)
46. Differential vulnerability to oxidative stress in rat cardiac myocytes versus fibroblasts. Zhang X, Azhar G, Nagano K, Wei JY, J Am Coll Cardiol 2001 38 2055 2062 10.1016/S0735-1097(01)01665-5 11738315 (Pubitemid 33116584)
47. Effects of reperfusion after coronary artery occlusion on post-infarction scar tissue. Connelly CM, Vogel WM, Wiegner AW, Osmers EL, Bing OH, Kloner RA, Dunn-Lanchantin DM, Franzblau C, Apstein CS, Circ Res 1985 57 562 577 10.1161/01.RES.57.4.562 4042284 (Pubitemid 16233123)
48. Structure and mechanics of healing myocardial infarcts. Holmes JW, Borg TK, Covell JW, Annu Rev Biomed Eng 2005 7 223 253 10.1146/annurev.bioeng.7. 060804.100453 16004571 (Pubitemid 41170188)
49. Phase matching considerations in second harmonic generation from tissues: effects on emission directionality, conversion efficiency and observed morphology. Lacomb R, Nadiarnykh O, Townsend SS, Campagnola PJ, Opt Commun 2008 281 1823 1832 10.1016/j.optcom.2007.10.040 19343083 (Pubitemid 351274128)
50. Rate of collagen deposition during healing and ventricular remodeling after myocardial infarction in rat and dog models. Jugdutt BI, Joljart MJ, Khan MI, Circulation 1996 94 94 101 10.1161/01.CIR.94.1.94 8964124 (Pubitemid 126426405)
51. Matrix metalloproteinases and myocardial infarction. Phatharajaree W, Phrommintikul A, Chattipakorn N, Can J Cardiol 2007 23 727 733 10.1016/S0828-282X(07)70818-8 17622396 (Pubitemid 47272296)
52. Increased levels of laminin and collagen type VI may reflect early remodelling in patients with acute myocardial infarction. Dinh W, Bansemir L, Füth R, Nickl W, Stasch J-P, Coll-Barroso M, Lapp H, Bufe A, Wolfertz J, Scheffold T, Lankisch M, Acta Cardiol 2009 64 329 334 10.2143/AC.64.3.2038017 19593942
53. Collagen remodeling after myocardial infarction in the rat heart. Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ, Am J Pathol 1995 147 325 338 7639329
54. Sequential changes in laminin and type IV collagen in the infarct zone: immunohistochemical study in rat myocardial infarction. Morishita N, Kusachi S, Yamasaki S, Kondo J, Tsuji T, Jpn Circ J 1996 60 108 114 10.1253/jcj.60.108 8683853 (Pubitemid 26098041)
55. Global analysis of transcript and protein levels across the Plasmodium falciparum life cycle. Le Roch KG, Johnson JR, Florens L, Zhou Y, Santrosyan A, Grainger M, Yan SF, Williamson KC, Holder AA, Carucci DJ, Yates JR, Winzeler EA, Genome Res 2004 14 2308 2318 10.1101/gr.2523904 15520293 (Pubitemid 39517338)
56. Collagen XV is necessary for modeling of the extracellular matrix and its deficiency predisposes to cardiomyopathy. Rasi K, Piuhola J, Czabanka M, Sormunen R, Ilves M, Leskinen H, Rysä J, Kerkelä R, Janmey P, Heljasvaara R, Peuhkurinen K, Vuolteenaho O, Ruskoaho H, Vajkoczy P, Pihlajaniemi T, Eklund L, Circ Res 2010 107 1241 1252 10.1161/CIRCRESAHA.110. 222133 20847313
57. Periostin is essential for cardiac healing after acute myocardial infarction. Shimazaki M, Nakamura K, Kii I, Kashima T, Amizuka N, Li M, Saito M, Fukuda K, Nishiyama T, Kitajima S, Saga Y, Fukayama M, Sata M, Kudo A, J Exp Med 2008 205 295 303 10.1084/jem.20071297 18208976 (Pubitemid 351281595)
58. Accumulation of fibronectin in the heart after myocardial infarction: a putative stimulator of adhesion and proliferation of adipose-derived stem cells. Van Dijk A, Niessen HWM, Ursem W, Twisk JWR, Visser FC, van Milligen FJ, Cell Tissue Res 2008 332 289 298 10.1007/s00441-008-0573-0 18305959
59. Increased expression of fibronectin isoforms after myocardial infarction in rats. Ulrich MM, Janssen AM, Daemen MJ, Rappaport L, Samuel JL, Contard F, Smits JF, Cleutjens JP, J Mol Cell Cardiol 1997 29 2533 2543 10.1006/jmcc.1997.0486 9299376 (Pubitemid 27404445)
60. Absence of type VI collagen paradoxically improves cardiac function, structure, and remodeling after myocardial infarction. Luther DJ, Thodeti CK, Shamhart PE, Adapala RK, Hodnichak C, Weihrauch D, Bonaldo P, Chilian WM, Meszaros JG, Circ Res 2012 110 851 856 10.1161/CIRCRESAHA.111.252734 22343710
61. Elastin overexpression by cell-based gene therapy preserves matrix and prevents cardiac dilation. Li S-H, Sun Z, Guo L, Han M, Wood MFG, Ghosh N, Vitkin IA, Weisel RD, Li R-K, J Cell Mol Med 2012 16 2429 2439 10.1111/j.1582-4934.2012.01560.x 22435995
62. Focus on collagen: in vitro systems to study fibrogenesis and antifibrosis state of the art. Chen CZ, Raghunath M, Fibrogenesis Tissue Repair 2009 2 7 10.1186/1755-1536-2-7 20003476
63. Myocardial collagen matrix remodeling and congestive heart failure. Brilla CG, Rupp H, Cardiologia 1994 39 389 393 7634301
64. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, Muguruma Y, Tsuboi K, Itabashi Y, Ikeda Y, Ogawa S, Okano H, Hotta T, Ando K, Fukuda K, Blood 2004 104 3581 3587 10.1182/blood-2004-04-1488 15297308 (Pubitemid 39564430)
65. Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. Mazhari R, Hare JM, Nat Clin Pract Cardiovasc Med 2007 4 21 S26 17230212
66. Paracrine factors released by GATA-4 overexpressed mesenchymal stem cells increase angiogenesis and cell survival. Li H, Zuo S, He Z, Yang Y, Pasha Z, Wang Y, Xu M, Am J Physiol Heart Circ Physiol 2010 299 1772 H1781 10.1152/ajpheart.00557.2010 20870802
67. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Sadat S, Gehmert S, Song Y-H, Yen Y, Bai X, Gaiser S, Klein H, Alt E, Biochem Biophys Res Commun 2007 363 674 679 10.1016/j.bbrc.2007.09.058 17904522 (Pubitemid 47513683)
68. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Uemura R, Xu M, Ahmad N, Ashraf M, Circ Res 2006 98 1414 1421 10.1161/01.RES.0000225952.61196.39 16690882 (Pubitemid 43948066)
69. Mesenchymal stem cells over-expressing SDF-1 promote angiogenesis and improve heart function in experimental myocardial infarction in rats. Tang J, Wang J, Yang J, Kong X, Zheng F, Guo L, Zhang L, Huang Y, Eur J Cardiothorac Surg 2009 36 644 650 10.1016/j.ejcts.2009.04.052 19524448
70. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Deuse T, Peter C, Fedak PWM, Doyle T, Reichenspurner H, Zimmermann WH, Eschenhagen T, Stein W, Wu JC, Robbins RC, Schrepfer S, Circulation 2009 120 247 S254 10.1161/CIRCULATIONAHA.108.843680 19752375
71. Crosstalk between hepatocyte growth factor and integrin signaling pathways. Chan P-C, Chen S-Y, Chen C-H, Chen H-C, J Biomed Sci 2006 13 215 223 10.1007/s11373-005-9061-7 16496226
72. HGF/SF-met signaling in the control of branching morphogenesis and invasion. Zhang Y-W, Vande Woude GF, J Cell Biochem 2003 88 408 417 10.1002/jcb.10358 12520544 (Pubitemid 36119916)
73. Specific beta1 integrin site selectively regulates Akt/protein kinase B signaling via local activation of protein phosphatase 2A. Pankov R, Cukierman E, Clark K, Matsumoto K, Hahn C, Poulin B, Yamada KM, J Biol Chem 2003 278 18671 18681 10.1074/jbc.M300879200 12637511 (Pubitemid 36799495)
74. Paracrine interactions between mesenchymal stem cells affect substrate driven differentiation toward tendon and bone phenotypes. Sharma RI, Snedeker JG, PLoS One 2012 7 31504 10.1371/journal.pone.0031504 22355373
75. The effect of collagen-targeting platelet-derived growth factor on cellularization and vascularization of collagen scaffolds. Lin H, Chen B, Sun W, Zhao W, Zhao Y, Dai J, Biomaterials 2006 27 5708 5714 10.1016/j.biomaterials. 2006.07.023 16901540 (Pubitemid 44294823)
76. Fibulin-5 binds human smooth-muscle cells through alpha5beta1 and alpha4beta1 integrins, but does not support receptor activation. Lomas AC, Mellody KT, Freeman LJ, Bax DV, Shuttleworth CA, Kielty CM, Biochem J 2007 405 417 428 10.1042/BJ20070400 17472576 (Pubitemid 47172038)
77. Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors. Ball SG, Shuttleworth CA, Kielty CM, J Cell Mol Med 2007 11 1012 1030 10.1111/j.1582-4934.2007.00120.x 17979880 (Pubitemid 350037047)
78. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Silva GV, Litovsky S, Assad JAR, Sousa ALS, Martin BJ, Vela D, Coulter SC, Lin J, Ober J, Vaughn WK, Branco RVC, Oliveira EM, He R, Geng Y-J, Willerson JT, Perin EC, Circulation 2005 111 150 156 10.1161/01.CIR.0000151812. 86142.45 15642764 (Pubitemid 40139725)
79. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. Behfar A, Yamada S, Crespo-Diaz R, Nesbitt JJ, Rowe LA, Perez-Terzic C, Gaussin V, Homsy C, Bartunek J, Terzic A, J Am Coll Cardiol 2010 56 721 734 10.1016/j.jacc.2010.03.066 20723802
80. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, Ishino K, Ishida H, Shimizu T, Kangawa K, Sano S, Okano T, Kitamura S, Mori H, Nat Med 2006 12 459 465 10.1038/nm1391 16582917
81. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Schuleri KH, Feigenbaum GS, Centola M, Weiss ES, Zimmet JM, Turney J, Kellner J, Zviman MM, Hatzistergos KE, Detrick B, Conte JV, McNiece I, Steenbergen C, Lardo AC, Hare JM, Eur Heart J 2009 30 2722 2732 10.1093/eurheartj/ehp265 19586959